investment

Hims & Hers Spikes; Will The FDA Blow The Door Open On Peptide Compounding?

ALLISON GATLIN

2 min read

0 likes

⚡ Quantum Brief

Hims & Hers stock surged Thursday after the FDA announced its advisory committee will review whether compounding pharmacies can legally produce specific peptides, a decision expected this summer. The ruling could overturn a 2023 FDA restriction on peptide compounding, potentially expanding market access for telehealth providers like Hims, which specializes in weight-loss and wellness treatments. Analysts call the development a "clear positive" for Hims, as peptide-based therapies—including those for obesity and anti-aging—could see broader distribution if compounding is permitted. The news follows Hims’ recent deal to sell Novo Nordisk’s branded weight-loss drugs, reinforcing its position in the lucrative telehealth and metabolic health sectors. A favorable FDA decision may unlock significant revenue streams for compounding pharmacies and telehealth platforms, reshaping the regulatory landscape for peptide-based medications.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

BREAKING: Market Keeps Rising; Netflix Dives LateHims stock jumped Thursday after the Food and Drug Administration said its advisors would weigh in on whether compounding pharmacies can make specific peptides. The decision this summer could reverse a 2023 ruling from the agency. The news is a "clear positive" for Hims & Hers Health (HIMS), Leerink Partners analyst Michael Cherny said in a report. Hims is a… 3/09/2026 Hims stock rocketed Monday after the telehealth company announced a deal to sell Novo Nordisk's branded weight-loss drugs on its... 3/09/2026 Hims stock rocketed Monday after the telehealth company announced a... Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!Get market updates, educational videos, webinars, and stock analysis.Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.©2026 Investor’s Business Daily, LLC.

Read Original

Source Information

Source: Investor's Business Daily

Website: https://www.investors.com/feed/

Discussion

0 professional contributions

Be the first to add a constructive contribution.